Hypomelanotic Disorder Overview

Save information for later
Sign Up

Learn About Hypomelanotic Disorder

What is the definition of Hypomelanotic Disorder?
Hypomelanotic disorder is a term that refers to types of skin conditions in which melanocytes (pigment cells) have a loss of pigment. Types of hypomelanotic disorders include vitiligo, ash leaf spots, and idiopathic guttate hypomelanosis, among others.
What are the symptoms of Hypomelanotic Disorder?
Symptoms of hypomelanotic disorders include loss of pigmentation that varies by the type of disorder. Symptoms of vitiligo include a complete loss of pigment in the skin that appears as well-delineated spots and patches. Symptoms of ash leaf spots include oval flattened areas of skin that lack pigment and angiofibromas on the face. Symptoms of idiopathic guttate hypomelanosis include small white flattened areas on sun-exposed skin areas.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Hypomelanotic Disorder?
Treatment for hypomelanotic disorders depends on the type. Treatment for vitiligo may include corticosteroids, tacrolimus, pimecrolimus, ultraviolet B and PUVA therapy, self-tanning creams, and skin grafting. Treatment for ash leaf spots may include laser therapy. Treatment for idiopathis guttate hypomelanosis is not necessary.
Who are the top Hypomelanotic Disorder Local Doctors?
Amit G. Pandya
Elite in Hypomelanotic Disorder
Dr. Amit G. Pandya
Dermatology
Elite in Hypomelanotic Disorder
Dr. Amit G. Pandya
Dermatology

Sunnyvale Center (401)

401 Old San Francisco Road, Level 2, 
Sunnyvale, CA 
650-934-7676
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amit Pandya is a Dermatologist in Sunnyvale, California. Dr. Pandya is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. His top areas of expertise are Vitiligo, Hypomelanotic Disorder, Porphyria Cutanea Tarda, Melasma, and Thrombectomy. Dr. Pandya is currently accepting new patients.

Anuradha Bishnoi
Elite in Hypomelanotic Disorder
Dr. Anuradha Bishnoi
Dermatology
Elite in Hypomelanotic Disorder
Dr. Anuradha Bishnoi
Dermatology

UPMC North Hills Dermatology

9000 Brooktree Road, Suite 200, 
Wexford, PA 
724-933-1320
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Anuradha Bishnoi, MD, specializes in dermatology. She practices at UPMC North Hills Dermatology and UPMC Shadyside Dermatology. Dr. Bishnoi received her medical degree from Maharshi Dayanand University and completed her residency at the Postgraduate Institute of Medical Education and Research. Dr. Bishnoi is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. Her top areas of expertise are Hypomelanotic Disorder, Vitiligo, Lichen Planus, and Melasma.

 
 
 
 
Learn about our expert tiers
Learn More
Nanja Van Geel
Elite in Hypomelanotic Disorder
Nanja Van Geel
Elite in Hypomelanotic Disorder
Nanja Van Geel
Gent, VLG, BE 

Nanja Van Geel practices in Gent, Belgium. Van Geel is rated as an Elite expert by MediFind in the treatment of Hypomelanotic Disorder. Their top areas of expertise are Vitiligo, Hypomelanotic Disorder, Piebaldism, and Alopecia Areata.

View All Doctors
What are the latest Hypomelanotic Disorder Clinical Trials?
A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

View All Clinical Trials